Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Läubli H[au]:

Sialic acids in cancer biology and immunity. Pearce OM et al. Glycobiology. (2016)

The immune system and cancer evasion strategies: therapeutic concepts. Muenst S et al. J Intern Med. (2016)

Cancer Immunotherapy. Pearce OMT et al. Glycobiology. (2018)

Search results

Items: 36

1.

Successful Treatment of Immune Checkpoint Inhibitor-Induced Diabetes Mellitus With Infliximab.

Trinh B, Donath MY, Läubli H.

Diabetes Care. 2019 Jul 15. pii: dc190908. doi: 10.2337/dc19-0908. [Epub ahead of print] No abstract available.

PMID:
31308021
2.

Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer.

Berner F, Bomze D, Diem S, Ali OH, Fässler M, Ring S, Niederer R, Ackermann CJ, Baumgaertner P, Pikor N, Cruz CG, van de Veen W, Akdis M, Nikolaev S, Läubli H, Zippelius A, Hartmann F, Cheng HW, Hönger G, Recher M, Goldman J, Cozzio A, Früh M, Neefjes J, Driessen C, Ludewig B, Hegazy AN, Jochum W, Speiser DE, Flatz L.

JAMA Oncol. 2019 Apr 25. doi: 10.1001/jamaoncol.2019.0402. [Epub ahead of print] Erratum in: JAMA Oncol. 2019 Jul 1;5(7):1070.

3.

Siglec-9 Regulates an Effector Memory CD8+ T-cell Subset That Congregates in the Melanoma Tumor Microenvironment.

Haas Q, Boligan KF, Jandus C, Schneider C, Simillion C, Stanczak MA, Haubitz M, Seyed Jafari SM, Zippelius A, Baerlocher GM, Läubli H, Hunger RE, Romero P, Simon HU, von Gunten S.

Cancer Immunol Res. 2019 May;7(5):707-718. doi: 10.1158/2326-6066.CIR-18-0505. Epub 2019 Apr 15.

PMID:
30988027
4.

Publisher Correction: Uncoupling protein 2 reprograms the tumor microenvironment to support the anti-tumor immune cycle.

Cheng WC, Tsui YC, Ragusa S, Koelzer VH, Mina M, Franco F, Läubli H, Tschumi B, Speiser D, Romero P, Zippelius A, Petrova TV, Mertz K, Ciriello G, Ho PC.

Nat Immunol. 2019 Apr;20(4):515-516. doi: 10.1038/s41590-019-0359-4.

PMID:
30862953
5.

Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint blockade for melanoma.

Trinh B, Sanchez GO, Herzig P, Läubli H.

J Immunother Cancer. 2019 Feb 21;7(1):52. doi: 10.1186/s40425-019-0528-x.

6.

A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung Cancer.

Trefny MP, Rothschild SI, Uhlenbrock F, Rieder D, Kasenda B, Stanczak MA, Berner F, Kashyap AS, Kaiser M, Herzig P, Poechtrager S, Thommen DS, Geier F, Savic S, Jermann P, Alborelli I, Schaub S, Stenner F, Früh M, Trajanoski Z, Flatz L, Mertz KD, Zippelius A, Läubli H.

Clin Cancer Res. 2019 May 15;25(10):3026-3034. doi: 10.1158/1078-0432.CCR-18-3041. Epub 2019 Feb 14.

PMID:
30765392
7.

Uncoupling protein 2 reprograms the tumor microenvironment to support the anti-tumor immune cycle.

Cheng WC, Tsui YC, Ragusa S, Koelzer VH, Mina M, Franco F, Läubli H, Tschumi B, Speiser D, Romero P, Zippelius A, Petrova TV, Mertz K, Ciriello G, Ho PC.

Nat Immunol. 2019 Feb;20(2):206-217. doi: 10.1038/s41590-018-0290-0. Epub 2019 Jan 21. Erratum in: Nat Immunol. 2019 Apr;20(4):515-516.

PMID:
30664764
8.

Treatment of mycophenolate-resistant immune-related organizing pneumonia with infliximab.

Ortega Sanchez G, Jahn K, Savic S, Zippelius A, Läubli H.

J Immunother Cancer. 2018 Sep 3;6(1):85. doi: 10.1186/s40425-018-0400-4.

9.

Immune tumor board: integral part in the multidisciplinary management of cancer patients treated with cancer immunotherapy.

Läubli H, Dirnhofer S, Zippelius A.

Virchows Arch. 2019 Apr;474(4):485-495. doi: 10.1007/s00428-018-2435-9. Epub 2018 Aug 25.

PMID:
30143868
10.

Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells.

Stanczak MA, Siddiqui SS, Trefny MP, Thommen DS, Boligan KF, von Gunten S, Tzankov A, Tietze L, Lardinois D, Heinzelmann-Schwarz V, von Bergwelt-Baildon M, Zhang W, Lenz HJ, Han Y, Amos CI, Syedbasha M, Egli A, Stenner F, Speiser DE, Varki A, Zippelius A, Läubli H.

J Clin Invest. 2018 Nov 1;128(11):4912-4923. doi: 10.1172/JCI120612. Epub 2018 Sep 24.

11.

Cancer Immunotherapy.

Pearce OMT, Läubli H.

Glycobiology. 2018 Sep 1;28(9):638-639. doi: 10.1093/glycob/cwy069. No abstract available.

PMID:
30084981
12.

Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events.

Läubli H, Balmelli C, Kaufmann L, Stanczak M, Syedbasha M, Vogt D, Hertig A, Müller B, Gautschi O, Stenner F, Zippelius A, Egli A, Rothschild SI.

J Immunother Cancer. 2018 May 22;6(1):40. doi: 10.1186/s40425-018-0353-7.

13.

Immunotherapy in head and neck cancer - scientific rationale, current treatment options and future directions.

Rothschild U, Muller L, Lechner A, Schlösser HA, Beutner D, Läubli H, Zippelius A, Rothschild SI.

Swiss Med Wkly. 2018 May 14;148:w14625. doi: 10.4414/smw.2018.14625. eCollection 2018. Review.

14.

The multi-receptor inhibitor axitinib reverses tumor-induced immunosuppression and potentiates treatment with immune-modulatory antibodies in preclinical murine models.

Läubli H, Müller P, D'Amico L, Buchi M, Kashyap AS, Zippelius A.

Cancer Immunol Immunother. 2018 May;67(5):815-824. doi: 10.1007/s00262-018-2136-x. Epub 2018 Feb 27.

PMID:
29487979
15.

Targeting sialic acid-Siglec interactions to reverse immune suppression in cancer.

Adams OJ, Stanczak MA, von Gunten S, Läubli H.

Glycobiology. 2018 Sep 1;28(9):640-647. doi: 10.1093/glycob/cwx108. Review.

PMID:
29309569
16.

The T cell repertoire in tumors overlaps with pulmonary inflammatory lesions in patients treated with checkpoint inhibitors.

Läubli H, Koelzer VH, Matter MS, Herzig P, Dolder Schlienger B, Wiese MN, Lardinois D, Mertz KD, Zippelius A.

Oncoimmunology. 2017 Oct 26;7(2):e1386362. doi: 10.1080/2162402X.2017.1386362. eCollection 2018.

17.

Cerebral vasculitis mimicking intracranial metastatic progression of lung cancer during PD-1 blockade.

Läubli H, Hench J, Stanczak M, Heijnen I, Papachristofilou A, Frank S, Zippelius A, Stenner-Liewen F.

J Immunother Cancer. 2017 Jun 20;5:46. doi: 10.1186/s40425-017-0249-y. eCollection 2017.

18.

Antimetastatic Properties of Low Molecular Weight Heparin.

Läubli H, Varki A, Borsig L.

J Clin Oncol. 2016 Jul 20;34(21):2560-1. doi: 10.1200/JCO.2016.66.4607. Epub 2016 May 16. No abstract available.

PMID:
27185851
19.

The immune system and cancer evasion strategies: therapeutic concepts.

Muenst S, Läubli H, Soysal SD, Zippelius A, Tzankov A, Hoeller S.

J Intern Med. 2016 Jun;279(6):541-62. doi: 10.1111/joim.12470. Epub 2016 Jan 8. Review.

20.

Sialic acids in cancer biology and immunity.

Pearce OM, Läubli H.

Glycobiology. 2016 Feb;26(2):111-28. doi: 10.1093/glycob/cwv097. Epub 2015 Oct 30. Review.

PMID:
26518624
21.

Lenalidomide monotherapy leads to a complete remission in refractory B-cell post-transplant lymphoproliferative disorder.

Läubli H, Tzankov A, Juskevicius D, Degen L, Rochlitz C, Stenner-Liewen F.

Leuk Lymphoma. 2016;57(4):945-8. doi: 10.3109/10428194.2015.1083563. Epub 2015 Oct 8. No abstract available.

PMID:
26295731
22.

Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma.

Läubli H, Balmelli C, Bossard M, Pfister O, Glatz K, Zippelius A.

J Immunother Cancer. 2015 Apr 21;3:11. doi: 10.1186/s40425-015-0057-1. eCollection 2015.

23.

Siglec receptors impact mammalian lifespan by modulating oxidative stress.

Schwarz F, Pearce OM, Wang X, Samraj AN, Läubli H, Garcia JO, Lin H, Fu X, Garcia-Bingman A, Secrest P, Romanoski CE, Heyser C, Glass CK, Hazen SL, Varki N, Varki A, Gagneux P.

Elife. 2015 Apr 7;4. doi: 10.7554/eLife.06184.

24.

Reply to Mackenzie: A comparison of Neu5Gc and α-gal xenoantigens.

Pearce OM, Samraj AN, Läubli H, Varki NM, Varki A.

Proc Natl Acad Sci U S A. 2015 Mar 24;112(12):E1405. doi: 10.1073/pnas.1500880112. Epub 2015 Feb 20. No abstract available.

25.

A red meat-derived glycan promotes inflammation and cancer progression.

Samraj AN, Pearce OM, Läubli H, Crittenden AN, Bergfeld AK, Banda K, Gregg CJ, Bingman AE, Secrest P, Diaz SL, Varki NM, Varki A.

Proc Natl Acad Sci U S A. 2015 Jan 13;112(2):542-7. doi: 10.1073/pnas.1417508112. Epub 2014 Dec 29.

26.

Lectin galactoside-binding soluble 3 binding protein (LGALS3BP) is a tumor-associated immunomodulatory ligand for CD33-related Siglecs.

Läubli H, Alisson-Silva F, Stanczak MA, Siddiqui SS, Deng L, Verhagen A, Varki N, Varki A.

J Biol Chem. 2014 Nov 28;289(48):33481-91. doi: 10.1074/jbc.M114.593129. Epub 2014 Oct 15.

27.

Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer.

Läubli H, Pearce OM, Schwarz F, Siddiqui SS, Deng L, Stanczak MA, Deng L, Verhagen A, Secrest P, Lusk C, Schwartz AG, Varki NM, Bui JD, Varki A.

Proc Natl Acad Sci U S A. 2014 Sep 30;111(39):14211-6. doi: 10.1073/pnas.1409580111. Epub 2014 Sep 15.

28.

Hormesis in cancer immunology: Does the quantity of an immune reactant matter?

Pearce OM, Läubli H, Bui J, Varki A.

Oncoimmunology. 2014 Jun 25;3:e29312. eCollection 2014.

29.

Corrigendum: involvement of a non-human sialic Acid in human cancer.

Samraj AN, Läubli H, Varki N, Varki A.

Front Oncol. 2014 Apr 22;4:83. doi: 10.3389/fonc.2014.00083. eCollection 2014. No abstract available.

30.

Inverse hormesis of cancer growth mediated by narrow ranges of tumor-directed antibodies.

Pearce OM, Läubli H, Verhagen A, Secrest P, Zhang J, Varki NM, Crocker PR, Bui JD, Varki A.

Proc Natl Acad Sci U S A. 2014 Apr 22;111(16):5998-6003. doi: 10.1073/pnas.1209067111. Epub 2014 Apr 7.

31.

Involvement of a non-human sialic Acid in human cancer.

Samraj AN, Läubli H, Varki N, Varki A.

Front Oncol. 2014 Feb 19;4:33. doi: 10.3389/fonc.2014.00033. eCollection 2014. Review.

32.

Selectins as mediators of lung metastasis.

Läubli H, Borsig L.

Cancer Microenviron. 2010 Feb 27;3(1):97-105. doi: 10.1007/s12307-010-0043-6.

33.

Selectins promote tumor metastasis.

Läubli H, Borsig L.

Semin Cancer Biol. 2010 Jun;20(3):169-77. doi: 10.1016/j.semcancer.2010.04.005. Epub 2010 May 7. Review.

34.

Selectin-mediated activation of endothelial cells induces expression of CCL5 and promotes metastasis through recruitment of monocytes.

Läubli H, Spanaus KS, Borsig L.

Blood. 2009 Nov 12;114(20):4583-91. doi: 10.1182/blood-2008-10-186585. Epub 2009 Sep 24.

35.

Heparins attenuate cancer metastasis: are selectins the link?

Laubli H, Borsig L.

Cancer Invest. 2009 Jun;27(5):474-81. doi: 10.1080/07357900802647136. Review.

36.

L-selectin facilitation of metastasis involves temporal induction of Fut7-dependent ligands at sites of tumor cell arrest.

Läubli H, Stevenson JL, Varki A, Varki NM, Borsig L.

Cancer Res. 2006 Feb 1;66(3):1536-42.

Supplemental Content

Loading ...
Support Center